Drug AYVAKIT Shows Long-Term Safety, Efficacy

AYVAKIT is a precision therapy designed to potently and selectively inhibit KIT D816V, the genetic mutation that drives approximately 95% of cases of indolent systemic mastocytosis. This targeted mechanism of action represents a shift from previous supportive care to a disease-modifying treatment. Indolent systemic mastocytosis (ISM) is the most common form of a rare blood disorder characterized by the abnormal accumulation of mast cells. Patients often experience a wide range of debilitating and unpredictable symptoms across multiple organ systems, including skin rashes, gastrointestinal issues, and severe allergic reactions. The recent four-year data from the PIONEER study demonstrated a sustained improvement in symptoms for patients taking AYVAKIT. The median duration of treatment in the long-term analysis was 40 months, showing durable benefits for those with the disease. The U.S. Food and Drug Administration (FDA) approved AYVAKIT for adults with indolent systemic mastocytosis in May 2023. This made it the first and only medicine approved by the FDA to treat this specific condition. Prior to its approval for indolent systemic mastocytosis, AYVAKIT was approved in June 2021 for advanced systemic mastocytosis. It is also approved for treating certain gastrointestinal stromal tumors (GIST). In the PIONEER trial, AYVAKIT was generally well-tolerated, with most adverse reactions being mild to moderate in severity. The most common side effects reported included eye edema, dizziness, peripheral edema, and flushing. The discontinuation rate due to treatment-related adverse events was low, at 3 percent, after a median follow-up of more than three years.